Drug intelligence / Profile preview

[123I]MNI-420

Development stage: Unknown
Lead developer: Institute for Neurodegenerative Disorders
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[123I]MNI-420 is a SPECT radiotracer developed for in vivo imaging of adenosine A2A receptors in the brain. It acts as an **antagonist** of A2A receptors and has been studied for its potential use in neurodegenerative disorders such as Parkinson's disease and Huntington's disease. The radiotracer rapidly enters the brain, displays uptake consistent with known A2A receptor densities, and has demonstrated good test-retest reliability.

Other names: 7-(2-(4-(2-Fluoro-4-[123I]iodophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine

Targets

ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on [123I]MNI-420.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [123I]MNI-420.

Explore the full profile